Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,352.00up ₹7.00 (0.52%)BSE ₹1,350.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,345.00.
30 Oct: open ₹1,345.00, high ₹1,363.70, low ₹1,345.00
52-week range of traded prices to 30 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,849 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.30
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.91
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.59%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,14,05957.9% delivered
Dr. Reddy's Laboratories share news and announcements
1,702 announcements, routine notices left out, newest first. Page 31 of 35.
Nov 2010
1 Nov · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Nomination, Governance & Compensation Committee of the Board of Directors of the Company has allotted 25,732 equity shares of Rs.5/- each of the Company, fully paid up, on October 30, 2010, to Director/Employees on exercise of their Stock Options as per the following details : (1) 22,472 equity shares of Rs.5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002; (2) 3,260 equity shares of Rs.5/- each underlying 3,260 ADRs pursuant to Dr.Reddy's Employees ADR Stock Option Scheme, 2007.
Oct 2010
23 Oct · Consolidated Result Updates - IFRS
23 Oct · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 127832 lacs for quarter ending on 30-SEP-2010 against Rs. 107322 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 22020 lacs for the quarter ending on 30-SEP-2010 against Rs. 19706 lacs for the quarter ending on 30-SEP-2009.11 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2010.
Sep 2010
Aug 2010
31 Aug · Business
Dr. Reddy's Laboratories Limited has informed the Exchange that the Governance & Compensation Committee of the Board of Directors of the Company has allotted 57,312 equity shares of Rs. 5/- each of the Company, fully paid up, on August 30, 2010, to Employees on exercise of their Stock Options as per the following details : (1) 53,304 equity shares of Rs.5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002; (2) 4,008 equity shares of Rs.5/- each underlying 4,008 ADRs pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007.12 Aug · Updates
Dr. Reddy'S Laboratories Limited has informed the Exchange with reference to earlier announcement regarding shareholder approval to the Scheme of Arrangement for issue of bonus debentures at a court convened meeting (the Scheme provides for issue of Unsecured, Redeemable, Non-convertible fully paid-up Bonus Debentures from the General Reserves, upto an amount of Rs. 520 crores in the ratio of six Bonus Debenture of Rs. 5 each for every share of Rs. 5 held by the shareholders) that the Hon'ble High Court of Andhra Pradesh at Hyderabad, vide its Order dated July 19, 2010 has approved the Scheme of Arrangement for issue of bonus debentures. A certified copy of the said Order has been obtained on August 11, 2010 by the Company and filed with the Registrar of Companies, Andhra Pradesh. The Company is in the process of seeking relevant regulatory approvals, including the approval of the Reserve Bank of India (RBI) which is a precondition to effectiveness of the Scheme. The Record Date will be fixed after all requisite approvals are received and the scheme has become effective in accordance with its terms.
Jul 2010
22 Jul · Change in Company Secretary
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on July 22, 2010 approved the appointment of Mr. Sandeep Poddar as Company Secretary and Compliance Officer in place of Mr. V S Suresh.22 Jul · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 125622 lacs for quarter ending on 30-JUN-2010 against Rs. 114417 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 24448 lacs for the quarter ending on 30-JUN-2010 against Rs. 22744 lacs for the quarter ending on 30-JUN-2009.8 Jul · Board meeting
Inter-alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2010.
Jun 2010
29 Jun · Dividend
Dr. Reddy'S Laboratories Limited has informed the Exchange that the dividend, which may be declared at the Annual General Meeting scheduled to be held on July 23, 2010, shall be paid to the shareholders on or after July 30, 2010.29 Jun · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Governance & Compensation Committee of the Board of Directors of the Company has allotted the following equity shares of Rs.5/- each of the Company, fully paid up, on June 28, 2010, to Directors / Employees on exercise of their Stock Options : (1) 134,825 equity shares of Rs.5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002; (2) 35,643 equity shares of Rs.5/- each underlying 35,643 ADRs pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007.10 Jun · Meeting
Dr. Reddy'S Laboratories Limited has informed the Exchange that the register of members and share transfer books of the Company would remain closed from July 6, 2010 to July 10, 2010 (both days inclusive) for the purpose of Annual General Meeting of the shareholders of the Company and for determining the shareholders who would be entitled for the payment of dividend, if declared at the forthcoming Annual General Meeting, scheduled to be held on July 23, 2010.2 Jun · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange that pursuant to Dr Reddy's Employees Stock Option Scheme, 2002, the Governance & Compensation Committee of the Board of Directors of the Company has allotted 128,410 equity shares of Rs.5/- each of the Company, fully paid up, on June 1, 2010, to Directors / Employees on exercise of their Stock Options.
May 2010
28 May · Outcome of Court Convened Meeting
Dr. Reddy'S Laboratories Limited has informed the Exchange that that at the Court Convened Meeting held on May 28, 2010 pursuant to the Order of the Hon'ble High Court at Judicature of Andhra Pradesh at Hyderabad dated April 21, 2010 passed in C.A. No. 286 of 2010, the shareholders of the Company have approved the proposed Scheme of Arrangement of the Company for issuance of bonus debentures with requisite majority.10 May · Disclosure
Dr. Reddy'S Laboratories Limited has informed the Exchange that "The Board of Directors of the Company in their meeting held on May 06, 2010, approved the grant of 9,600 stock options, exercisable at par value of Rs.5/- to the Independent Directors of the Company under "Dr. Reddy's Employees Stock Option Scheme, 2002" and also approved the grant of 7,200 stock options, exercisable at par value of Rs.5/- to the Independent Directors of the Company under "Dr. Reddy's Employees ADR Stock Option Scheme, 2007". Further the Compensation Committee of the Board of Directors of the Company in their meeting held on May 06, 2010 approved the grant of 275,070 stock options, exercisable at par value of Rs.5/- to the employees of the Company under "Dr. Reddy's Employees Stock Option Scheme, 2002" and also approved the grant of 51,460 stock options, exercisable at par value of Rs.5/- to the employees of the Company under "Dr. Reddy's Employees ADR Stock Option Scheme, 2007".6 May · Dividend
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Board of Directors at its meeting held on May 06, 2010 have recommended a final dividend of Rs.11.25 (225%) per equity share of Rs.5/- face value, subject to the approval of shareholders at the ensuing Annual General Meeting.6 May · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 685164 lacs for year ending on 31-MAR-2010 against Rs. 679037 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 35147 lacs for the year ending on 31-MAR-2010 against Rs. (91724) lacs for the year ending on 31-MAR-2009.6 May · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 440113 lacs for year ending on 31-MAR-2010 against Rs. 399963 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 84608 lacs for the year ending on 31-MAR-2010 against Rs. 56089 lacs for the year ending on 31-MAR-2009.6 May · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 115237 lacs for quarter ending on 31-MAR-2010 against Rs. 104583 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 25316 lacs for the quarter ending on 31-MAR-2010 against Rs. 15617 lacs for the quarter ending on 31-MAR-2009.
Apr 2010
26 Apr · Business
Dr. Reddy'S Laboratories Limited has informed the Exchange regarding a press release dated April 26, 2010, titled "Dr.Reddy's announces the Launch of Amlodipine Benazepril in US market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated April 15, 2010, titled "Dr. Reddy's introduces 'Dose Counter Inhalers' for the first time in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Apr · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2010 and recommend dividend, if any, for the financial year 2009-10.6 Apr · Results
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that the Company will announce and publish the audited annual financial results of the Company for the year ended March 31, 2010 instead of unaudited/ audited quarterly financial results for the quarter ended March 31, 2010.
Mar 2010
31 Mar · Corporate action
Dr. Reddy's Laboratories Ltd. has informed the Exchange that the Board of Directors of the Company at its meeting held on March 31, 2010, considered and approved the proposal for issuance of bonus debentures to shareholders of the Company from its General Reserves built from undistributed profits in terms of a scheme of arrangement under Sections 391-394 and other relevant provisions of the Companies Act, 1956 ("Scheme").The proposed Scheme provides that subject to necessary approvals, the Company would issue, upon effectiveness of the Scheme, unsecured, non-convertible, redeemable, fully paid up bonus debentures of the face value of Rs. 5/- each ("Bonus Debentures") to its shareholders on the record date to be determined by the board of directors, in the ratio of 6 Bonus Debentures for every 1 equity share of Rs. 5/- each held by a member of the Company. The draft Scheme was also approved by the Board of Directors at the meeting. The Bonus Debentures would carry a coupon rate to be determined by the board of directors, payable annually and would be redeemable at par at the end of thirty six months from the date of allotment. The Bonus Debentures are proposed to be rated and listed. The issue and allotment of debentures will account for an amount not exceeding Rs. 520 Crores. The above proposal is subject to the satisfaction of various conditions, including obtaining necessary approvals from the shareholders and regulatory authorities including those of the stock exchanges under the Listing Agreement, Reserve Bank of India and sanction of the scheme of arrangement by the High Court of Andhra Pradesh. Further, the Company has submitted to the Exchange a copy of Press Release dated March 31, 2010 titled "Dr. Reddy's board approves bonus debentures issue". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Mar · Board meeting
To consider a proposal for the issuance of bonus debentures by the Company to its shareholders.17 Mar · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated March 17, 2010, titled "Dr. Reddy's Custom Pharmaceutical Services (CPS) business commissions mPEG alcohol manufacturing facility and officially brands its Activated mPEG Products as PEGtech". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2010
26 Feb · Allotment of Equity Shares
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that "The Governance & Compensation Committee of the Board of Directors of the Company has allotted the following equity shares of Rs.5/- each of the Company, fully paid up on February 26, 2010, to Employees on exercise of their Stock Options. (a) 19,850 equity shares of Rs.5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002. (b) 500 equity shares of Rs.5/- each underlying 500 ADRs pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007".3 Feb · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated February 03, 2010, titled "Sanjeev Verma appointed as new Head of Corporate Communications and Branding". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
20 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 20, 2010, titled "Dr.Reddy's Q3 FY10 Financial Results- Revenues at Rs. 17,296 million, EBITDA at Rs. 3,666 million, Profits after Tax adjusted for impairment at Rs. 2,307 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Jan · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 170355 lacs for quarter ending on 31-DEC-2009 against Rs. 180499 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. (23307) lacs for the quarter ending on 31-DEC-2009 against Rs. 15916 lacs for the quarter ending on 31-DEC-2008.20 Jan · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 103136 lacs for quarter ending on 31-DEC-2009 against Rs. 95212 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 16842 lacs for the quarter ending on 31-DEC-2009 against Rs. 10367 lacs for the quarter ending on 31-DEC-2008.11 Jan · Board meeting
Inter alia to consider and approve the unaudited financial results of the Company for the quarter and nine months ended December 31, 2009.4 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 04, 2010, titled "Dr.Reddy's and Rheoscience announce headline results from First Phase III clinical trial of Balaglitazone (DRF 2593)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
9 Dec · Allotment of Equity Shares
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that "The Governance & Compensation Committee of the Board of Directors of the Company has allotted the following equity shares of Rs.5/- each of the Company, fully paid up on December 08, 2009, to Employees on exercise of their Stock Options. (a) 21,884 equity shares of Rs.5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002. (b) 1,450 equity shares of Rs.5/- each underlying 1,450 ADRs pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007".